24
Participants
Start Date
November 28, 2023
Primary Completion Date
April 30, 2024
Study Completion Date
April 30, 2025
Mitoxantrone hydrochloride liposome
Drug: Mitoxantrone hydrochloride liposome (16 mg/m\^2, 18 mg/m\^2, 20 mg/m\^2 and 22 mg/m\^2) will be administered by intravenous infusion on day 1 in a 3-week treatment cycle.
Capecitabine
Capecitabine (1000 mg/m\^2) will be administered orally in a 3-week treatment cycle, twice a day from day 1 to day 14 of each cycle.
Mitoxantrone hydrochloride liposome
Mitoxantrone hydrochloride liposome (16 mg/m\^2, 18 mg/m\^2, 20 mg/m\^2 and 22 mg/m\^2) will be administered by intravenous infusion on day 1 in a 4-week treatment cycle.
Capecitabine
Capecitabine (825 mg/m\^2) will be administered orally in a 4-week treatment cycle, twice a day from day 1 to day 21 of each cycle.
Cancer Hospital Chinese Academy of Medical Sciences, Beijing
Collaborators (1)
CSPC Ouyi Pharmaceutical Co., Ltd.
INDUSTRY
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
OTHER